BUZZ-Aeterna Zentaris Inc: HC Wainwright raises to "buy"
** Drug developer's shares up 5.6 pct at 56 cents
** Analysts at HC Wainwright raise rating to "buy" from "neutral" after the company says it plans to conduct confirmatory study on hormone deficiency drug-test after meeting with U.S. Food and Drug Administration
** FDA rejected the test on Nov. 6
** "If the studies are successful, we expect Macrilen to be in the market in the US in 2018 and in the EU in 2019. We project Macrilen revenues to grow to nearly $66 million by 2025," analysts wrote
** Up to Monday's close, stock had more than halved in the past 12 months
© Thomson Reuters 2017 All rights reserved.